Form 4: Catalyst Pharmaceuticals Director Acquires Shares Through Vesting of Restricted Stock Units

Director David S. Tierney acquired 1,413 shares of Catalyst Pharmaceuticals common stock through the vesting of restricted stock units.

Summary

• David S. Tierney, a director at Catalyst Pharmaceuticals, acquired 1,413 shares of common stock on December 9, 2024.
• The acquisition resulted from the vesting of restricted stock units.
• These restricted stock units vest in three equal tranches, with the first tranche vesting on December 8, 2024.
• The shares were delivered to Mr. Tierney on December 9, 2024.
• Following the transaction, Mr. Tierney directly owns 350,287 shares of common stock and 213,607 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is a positive sign that the director is acquiring shares, but it is not a major event that would significantly impact the company's valuation.

Positives

• The vesting of restricted stock units indicates that the director is meeting performance or time-based requirements.
• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine transaction related to executive compensation and is common in publicly traded companies. It reflects the standard practice of using equity-based compensation to align the interests of management and shareholders.

Comparison to Industry Standards

• The vesting of restricted stock units is a common practice in the pharmaceutical industry for compensating directors and executives.
• Many companies, such as Biogen and Amgen, use similar equity-based compensation plans to incentivize their leadership.
• The vesting schedule of 1/3rd per year is also a typical vesting schedule for restricted stock units.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates director confidence in the company.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Catalyst Pharmaceuticals, Director, David S. Tierney, Restricted Stock Units, Share Acquisition, Vesting, Insider Trading